Roth Capital rated Buy Concert Pharmaceuticals Inc. (NASDAQ: CNCE) on 09/22/2015. Previously Roth Capital rated Buy Concert Pharmaceuticals Inc. (NASDAQ: CNCE) on 03/19/2014., when the stock price was $13.92. Since then, Concert Pharmaceuticals Inc. has gained 12.00% as of 09/22/2015's recent price of $15.59.
If you would have followed the previous Roth Capital's recommendation on CNCE, you would have gained 11.99% of your investment in 552 days.



ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.

Marked as spam